Telomir Pharmaceuticals (NASDAQ: TELO) has announced new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, which could accelerate the development of new therapies for both veterinary and human patients.
Osteosarcoma is a rare but aggressive form of bone cancer that affects both humans and dogs. In humans, it is most commonly diagnosed in children and young adults, while in dogs, it occurs frequently in larger breeds. The similar biology of the disease in both species makes canine osteosarcoma a valuable model for studying potential treatments. Telomir-Zn's ability to inhibit growth in both human and canine cell lines at low concentrations suggests that it may target a fundamental mechanism shared across species.
Telomir is currently in discussions with The Ohio State University College of Veterinary Medicine to assess next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. The company's immediate focus, however, remains its triple-negative breast cancer (TNBC) program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC. The TNBC program is a critical near-term milestone, but the osteosarcoma findings open a new avenue for Telomir-Zn's potential applications.
The implications of this research are significant. If Telomir-Zn proves effective in canine osteosarcoma, it could provide a faster and more cost-effective pathway to evaluate the drug's efficacy in a naturally occurring disease that closely mirrors human osteosarcoma. This could accelerate the development of new treatments for a cancer that has seen limited therapeutic advances in recent decades. Moreover, the results add to the growing body of evidence that Telomir-Zn, which is designed to modulate intracellular metal homeostasis and epigenetic regulation, may have broad anti-cancer activity. The company's approach targets epigenetic and metabolic pathways implicated in cancer, a strategy that is gaining attention in oncology.
For investors, the news highlights Telomir's potential to expand its pipeline beyond TNBC. While the TNBC program remains the primary focus, the osteosarcoma research demonstrates the versatility of Telomir-Zn and could lead to additional indications. The company's collaboration with a leading veterinary institution like The Ohio State University College of Veterinary Medicine lends credibility to the findings and may facilitate further studies. To view the full press release, visit https://nnw.fm/laeGH. For more information about Telomir Pharmaceuticals, including the latest news and updates, visit the company's newsroom at https://nnw.fm/TELO.
As Telomir advances its TNBC program and explores the potential of Telomir-Zn in osteosarcoma, the company is positioning itself at the intersection of human and veterinary oncology. The successful development of a dual-purpose therapeutic could not only benefit patients but also provide a strategic advantage in a competitive biotechnology landscape. The next steps, including the potential in vivo study in canine osteosarcoma, will be closely watched by investors and the scientific community alike.
